Published in J Interferon Cytokine Res on July 25, 2011
Re-entry into quiescence protects hematopoietic stem cells from the killing effect of chronic exposure to type I interferons. J Exp Med (2014) 1.18
Cytokines in autoimmunity: role in induction, regulation, and treatment. J Interferon Cytokine Res (2011) 1.00
Mediators of inflammation and their effect on resident renal cells: implications in lupus nephritis. Clin Dev Immunol (2013) 0.95
IL-17 and IL-23 in lupus nephritis - association to histopathology and response to treatment. BMC Immunol (2015) 0.92
Interferons in autoimmune and inflammatory diseases: regulation and roles. J Interferon Cytokine Res (2011) 0.91
Biomarkers in systemic lupus erythematosus: challenges and prospects for the future. Ther Adv Musculoskelet Dis (2013) 0.88
Contributions of B cells to lupus pathogenesis. Mol Immunol (2013) 0.87
Seeking balance: Potentiation and inhibition of multiple sclerosis autoimmune responses by IL-6 and IL-10. Cytokine (2015) 0.85
Small molecules in the treatment of systemic lupus erythematosus. Clin Immunol (2012) 0.83
Resistin as a potential marker of renal disease in lupus nephritis. Clin Exp Immunol (2015) 0.81
PPARγ Agonists in Adaptive Immunity: What Do Immune Disorders and Their Models Have to Tell Us? PPAR Res (2013) 0.80
Arginase-1-dependent promotion of TH17 differentiation and disease progression by MDSCs in systemic lupus erythematosus. Sci Transl Med (2016) 0.78
The protective effect of GM-CSF on serum-induced neutrophil apoptosis in juvenile systemic lupus erythematosus patients. Clin Rheumatol (2014) 0.77
Melanocortin peptides: potential targets in systemic lupus erythematosus. Inflammation (2015) 0.77
Increased activation of toll-like receptors-7 and -8 of peripheral blood mononuclear cells and upregulated serum cytokines in patients with pediatric systemic lupus erythematosus. Int J Clin Exp Med (2015) 0.76
IL-2, IL-4, IFN-γ or TNF-α enhances BAFF-stimulated cell viability and survival by activating Erk1/2 and S6K1 pathways in neoplastic B-lymphoid cells. Cytokine (2016) 0.75
IL-1β and IL-6 Are Highly Expressed in RF+IgE+ Systemic Lupus Erythematous Subtype. J Immunol Res (2017) 0.75
C/EBP β mRNA expression is upregulated and positively correlated with the expression of TNIP1/TNFAIP3 in peripheral blood mononuclear cells from patients with systemic lupus erythematosus. Exp Ther Med (2016) 0.75
IL-17 and Th17 Cells. Annu Rev Immunol (2009) 23.02
Genome-wide association scan in women with systemic lupus erythematosus identifies susceptibility variants in ITGAM, PXK, KIAA1542 and other loci. Nat Genet (2008) 12.51
Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A (2003) 11.65
Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med (2003) 11.23
The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity (2008) 10.55
Signalling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol (2003) 10.29
Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. Science (2001) 8.14
Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet (2008) 7.37
A large-scale replication study identifies TNIP1, PRDM1, JAZF1, UHRF1BP1 and IL10 as risk loci for systemic lupus erythematosus. Nat Genet (2009) 5.75
Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood (2011) 5.61
Immune interferon in the circulation of patients with autoimmune disease. N Engl J Med (1979) 5.58
New insights into the regulation of T cells by gamma(c) family cytokines. Nat Rev Immunol (2009) 5.57
Gp130 and the interleukin-6 family of cytokines. Annu Rev Immunol (1997) 5.38
Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. Arthritis Rheum (2005) 4.84
Polymorphisms in the tyrosine kinase 2 and interferon regulatory factor 5 genes are associated with systemic lupus erythematosus. Am J Hum Genet (2005) 4.80
Follicular helper T cells are required for systemic autoimmunity. J Exp Med (2009) 4.25
Interleukin 6: from bench to bedside. Nat Clin Pract Rheumatol (2006) 4.10
Cracking the BAFF code. Nat Rev Immunol (2009) 3.95
Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus. J Immunol (2001) 3.87
The role of TNF superfamily members in T-cell function and diseases. Nat Rev Immunol (2009) 3.72
High serum IFN-alpha activity is a heritable risk factor for systemic lupus erythematosus. Genes Immun (2007) 3.59
Induction of interferon-alpha production in plasmacytoid dendritic cells by immune complexes containing nucleic acid released by necrotic or late apoptotic cells and lupus IgG. Arthritis Rheum (2004) 3.57
Type-I interferon receptor deficiency reduces lupus-like disease in NZB mice. J Exp Med (2003) 3.50
Basophils and the T helper 2 environment can promote the development of lupus nephritis. Nat Med (2010) 3.24
Directing transition from innate to acquired immunity: defining a role for IL-6. J Immunol (2005) 3.17
A pivotal role for the natural interferon alpha-producing cells (plasmacytoid dendritic cells) in the pathogenesis of lupus. J Exp Med (2001) 3.03
In vivo treatment of (NZB X NZW)F1 lupus-like nephritis with monoclonal antibody to gamma interferon. J Exp Med (1987) 2.93
Role of interleukin 10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus. J Exp Med (1995) 2.89
Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies. Lupus (2000) 2.81
The ubiquitin-editing enzyme A20 (TNFAIP3) is a central regulator of immunopathology. Trends Immunol (2009) 2.74
Cross-regulation of TNF and IFN-alpha in autoimmune diseases. Proc Natl Acad Sci U S A (2005) 2.73
IL-21 has a pathogenic role in a lupus-prone mouse model and its blockade with IL-21R.Fc reduces disease progression. J Immunol (2007) 2.71
BAFF and MyD88 signals promote a lupuslike disease independent of T cells. J Exp Med (2007) 2.70
Association of the IRF5 risk haplotype with high serum interferon-alpha activity in systemic lupus erythematosus patients. Arthritis Rheum (2008) 2.62
Regulation of B cell tolerance by the lupus susceptibility gene Ly108. Science (2006) 2.58
A critical role for IL-21 receptor signaling in the pathogenesis of systemic lupus erythematosus in BXSB-Yaa mice. Proc Natl Acad Sci U S A (2009) 2.46
Th17 and natural Treg cell population dynamics in systemic lupus erythematosus. Arthritis Rheum (2009) 2.43
Serum interferon levels in patients with systemic lupus erythematosus. Arthritis Rheum (1982) 2.40
Cutting edge: autoimmune disease risk variant of STAT4 confers increased sensitivity to IFN-alpha in lupus patients in vivo. J Immunol (2009) 2.39
Identification of IRAK1 as a risk gene with critical role in the pathogenesis of systemic lupus erythematosus. Proc Natl Acad Sci U S A (2009) 2.31
Microarray analysis of interferon-regulated genes in SLE. Autoimmunity (2003) 2.24
Th1/Th2 balance of peripheral T helper cells in systemic lupus erythematosus. Arthritis Rheum (1999) 2.18
Neutralization of interferon-alpha/beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus. Arthritis Rheum (2009) 2.14
The role of IL-23/IL-17 axis in lupus nephritis. J Immunol (2009) 2.06
Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum (2010) 1.86
Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus. Arthritis Rheum (2000) 1.84
Interleukin 6 (IL-6) deficiency delays lupus nephritis in MRL-Faslpr mice: the IL-6 pathway as a new therapeutic target in treatment of autoimmune kidney disease in systemic lupus erythematosus. J Rheumatol (2009) 1.84
Characterization of heterogeneity in the molecular pathogenesis of lupus nephritis from transcriptional profiles of laser-captured glomeruli. J Clin Invest (2004) 1.82
Genetic association of interleukin-21 polymorphisms with systemic lupus erythematosus. Ann Rheum Dis (2007) 1.82
BLyS and APRIL form biologically active heterotrimers that are expressed in patients with systemic immune-based rheumatic diseases. J Immunol (2002) 1.77
Type I IFN protects against murine lupus. J Immunol (2004) 1.71
IL-10 family of cytokines. Cytokine Growth Factor Rev (2010) 1.70
Collaboration, genetic associations, and lupus erythematosus. N Engl J Med (2008) 1.66
Cytokine profile in systemic lupus erythematosus, rheumatoid arthritis, and other rheumatic diseases. J Clin Immunol (1993) 1.66
IFN-gamma receptor signaling is essential for the initiation, acceleration, and destruction of autoimmune kidney disease in MRL-Fas(lpr) mice. J Immunol (1998) 1.65
Serum interleukin 10 titers in systemic lupus erythematosus reflect disease activity. Lupus (1995) 1.63
Excessive production of IFN-gamma in patients with systemic lupus erythematosus and its contribution to induction of B lymphocyte stimulator/B cell-activating factor/TNF ligand superfamily-13B. J Immunol (2008) 1.56
An etiopathogenic role for the type I IFN system in SLE. Trends Immunol (2001) 1.54
Elevated interleukin-10 levels correlated with disease activity in systemic lupus erythematosus. Clin Exp Rheumatol (1998) 1.52
Glomerular accumulation of plasmacytoid dendritic cells in active lupus nephritis: role of interleukin-18. Arthritis Rheum (2008) 1.52
IFN-gamma receptor deletion prevents autoantibody production and glomerulonephritis in lupus-prone (NZB x NZW)F1 mice. J Immunol (1998) 1.50
Genetic regulation of serum cytokines in systemic lupus erythematosus. Transl Res (2009) 1.49
Differential contribution of IL-4 and STAT6 vs STAT4 to the development of lupus nephritis. J Immunol (2003) 1.47
Type I Interferon controls the onset and severity of autoimmune manifestations in lpr mice. J Autoimmun (2003) 1.46
Trait-stratified genome-wide association study identifies novel and diverse genetic associations with serologic and cytokine phenotypes in systemic lupus erythematosus. Arthritis Res Ther (2010) 1.45
Tumour necrosis factor alpha and its soluble receptors parallel clinical disease and autoimmune activity in systemic lupus erythematosus. Br J Rheumatol (1996) 1.42
Adverse events and efficacy of TNF-alpha blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients. Rheumatology (Oxford) (2009) 1.41
B cell receptor and BAFF receptor signaling regulation of B cell homeostasis. J Immunol (2009) 1.36
The role of tumor necrosis factor-alpha in systemic lupus erythematosus. Arthritis Res Ther (2008) 1.33
Increased excretions of beta2-microglobulin, IL-6, and IL-8 and decreased excretion of Tamm-Horsfall glycoprotein in urine of patients with active lupus nephritis. Nephron (2000) 1.31
Anti-interleukin-6 monoclonal antibody inhibits autoimmune responses in a murine model of systemic lupus erythematosus. Immunology (2006) 1.28
Cytokines as therapeutic targets in SLE. Nat Rev Rheumatol (2010) 1.25
Presence of tumor necrosis factor alpha and interleukin-6 in renal mesangial cells of lupus nephritis patients. Hum Pathol (1995) 1.24
A polymorphism within IL21R confers risk for systemic lupus erythematosus. Arthritis Rheum (2009) 1.23
Membranous glomerulonephritis development with Th2-type immune deviations in MRL/lpr mice deficient for IL-27 receptor (WSX-1). J Immunol (2005) 1.18
Elevated production of B cell chemokine CXCL13 is correlated with systemic lupus erythematosus disease activity. J Clin Immunol (2009) 1.16
Drug-induced lupus: an update. Autoimmun Rev (2010) 1.13
Preliminary results of safety and efficacy of the interleukin 1 receptor antagonist anakinra in patients with severe lupus arthritis. Ann Rheum Dis (2004) 1.13
IFNalpha kinoid vaccine-induced neutralizing antibodies prevent clinical manifestations in a lupus flare murine model. Proc Natl Acad Sci U S A (2009) 1.11
Cytokine balance in kidney tissue from lupus nephritis patients. Rheumatology (Oxford) (2003) 1.11
Activation of natural interferon-alpha producing cells by apoptotic U937 cells combined with lupus IgG and its regulation by cytokines. J Autoimmun (2001) 1.10
Targeting BAFF in autoimmunity. Curr Opin Immunol (2010) 1.08
Interferon-gamma gene polymorphisms associated with susceptibility to systemic lupus erythematosus. Ann Rheum Dis (2009) 1.07
High levels of TH2 cytokine gene expression in systemic lupus erythematosus. Rev Invest Clin (1996) 1.06
Serum and urinary interleukin-6 in systemic lupus erythematosus. Lupus (1996) 1.05
Urinary levels of IL-6 in patients with active lupus nephritis. Clin Nephrol (1993) 1.05
Type I interferons produced by resident renal cells may promote end-organ disease in autoantibody-mediated glomerulonephritis. J Immunol (2009) 1.04
IFN-alpha regulates IL-21 and IL-21R expression in human NK and T cells. J Leukoc Biol (2004) 1.03
Measurement of intracellular interferon-gamma and interleukin-4 in whole blood T lymphocytes from patients with systemic lupus erythematosus. Immunol Lett (2000) 0.92
Low levels of interleukin-1 receptor antagonist coincide with kidney involvement in systemic lupus erythematosus. Br J Rheumatol (1997) 0.89
Development of lupus in BXSB mice is independent of IL-4. J Immunol (2000) 0.88
IL-1RA in refractory systemic lupus erythematosus. Lupus (2004) 0.86
The lipopolysaccharide-triggered mesangial transcriptome: Evaluating the role of interferon regulatory factor-1. Kidney Int (2005) 0.84
B cell immunotherapy in autoimmunity--2010 update. Mol Immunol (2010) 0.84
T(H)1/T(H)2 cytokine profile, metalloprotease-9 activity and hormonal status in pregnant rheumatoid arthritis and systemic lupus erythematosus patients. Clin Exp Immunol (2003) 0.83
Promotion of lupus in NZB x NZWF1 mice by plasmids encoding interferon (IFN)-gamma but not by those encoding interleukin (IL)-4. J Comp Pathol (2002) 0.82
Measurement of interleukin-1 receptor antagonist in patients with systemic lupus erythematosus could predict renal manifestation of the disease. Hum Immunol (2010) 0.80
An update on belimumab for the treatment of lupus. Biologics (2011) 0.79
IL-4Ralpha polymorphism in regulation of IL-4 synthesis by T cells: implication in susceptibility to a subset of murine lupus. Int Immunol (2006) 0.78
Regulation of B cell tolerance by the lupus susceptibility gene Ly108. Science (2006) 2.58
Combined deficiency of proapoptotic regulators Bim and Fas results in the early onset of systemic autoimmunity. Immunity (2008) 2.48
Identification of autoantibody clusters that best predict lupus disease activity using glomerular proteome arrays. J Clin Invest (2005) 2.36
Identification of IRAK1 as a risk gene with critical role in the pathogenesis of systemic lupus erythematosus. Proc Natl Acad Sci U S A (2009) 2.31
DGKE variants cause a glomerular microangiopathy that mimics membranoproliferative GN. J Am Soc Nephrol (2012) 1.93
The green tea polyphenol (-)-epigallocatechin-3-gallate ameliorates experimental immune-mediated glomerulonephritis. Kidney Int (2011) 1.72
Use of a novel elution regimen reveals the dominance of polyreactive antinuclear autoantibodies in lupus kidneys. Arthritis Rheum (2003) 1.63
Excreted urinary mediators in an animal model of experimental immune nephritis with potential pathogenic significance. Arthritis Rheum (2007) 1.62
Toll-like receptor signaling pathways--therapeutic opportunities. Mediators Inflamm (2010) 1.58
Kallikrein genes are associated with lupus and glomerular basement membrane-specific antibody-induced nephritis in mice and humans. J Clin Invest (2009) 1.54
Critical role of TLR7 in the acceleration of systemic lupus erythematosus in TLR9-deficient mice. J Autoimmun (2009) 1.51
Elevated urinary VCAM-1, P-selectin, soluble TNF receptor-1, and CXC chemokine ligand 16 in multiple murine lupus strains and human lupus nephritis. J Immunol (2007) 1.49
Requirement of myeloid cell-specific Fas expression for prevention of systemic autoimmunity in mice. Arthritis Rheum (2012) 1.48
T cell hyperactivity in lupus as a consequence of hyperstimulatory antigen-presenting cells. J Clin Invest (2005) 1.45
Strain distribution pattern of susceptibility to immune-mediated nephritis. J Immunol (2004) 1.34
SLE peripheral blood B cell, T cell and myeloid cell transcriptomes display unique profiles and each subset contributes to the interferon signature. PLoS One (2013) 1.25
Lupus susceptibility genes may breach tolerance to DNA by impairing receptor editing of nuclear antigen-reactive B cells. J Immunol (2007) 1.22
Pathogenic profiles and molecular signatures of antinuclear autoantibodies rescued from NZM2410 lupus mice. J Exp Med (2004) 1.22
Genetic dissection of SLE: SLE1 and FAS impact alternate pathways leading to lymphoproliferative autoimmunity. J Exp Med (2002) 1.22
CXCR4/CXCL12 hyperexpression plays a pivotal role in the pathogenesis of lupus. J Immunol (2009) 1.22
Experimental anti-GBM disease as a tool for studying spontaneous lupus nephritis. Clin Immunol (2007) 1.21
Enhanced susceptibility to end-organ disease in the lupus-facilitating NZW mouse strain. Arthritis Rheum (2003) 1.18
Evidence for intranasal antinuclear autoantibodies in patients with chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol (2011) 1.17
Metabolic disturbances associated with systemic lupus erythematosus. PLoS One (2012) 1.15
p21Cip1 is required for the development of monocytes and their response to serum transfer-induced arthritis. Am J Pathol (2006) 1.14
Shared signaling networks active in B cells isolated from genetically distinct mouse models of lupus. J Clin Invest (2007) 1.14
Nephritogenic anti-DNA antibodies regulate gene expression in MRL/lpr mouse glomerular mesangial cells. Arthritis Rheum (2006) 1.14
Innate stimuli accentuate end-organ damage by nephrotoxic antibodies via Fc receptor and TLR stimulation and IL-1/TNF-alpha production. J Immunol (2006) 1.13
Urine VCAM-1 as a marker of renal pathology activity index in lupus nephritis. Arthritis Res Ther (2012) 1.10
Cellular and molecular pathogenesis of systemic lupus erythematosus: lessons from animal models. Arthritis Res Ther (2011) 1.05
The CDK domain of p21 is a suppressor of IL-1beta-mediated inflammation in activated macrophages. Eur J Immunol (2009) 1.04
Type I interferons produced by resident renal cells may promote end-organ disease in autoantibody-mediated glomerulonephritis. J Immunol (2009) 1.04
Bim deficiency leads to exacerbation and prolongation of joint inflammation in experimental arthritis. Arthritis Rheum (2006) 1.03
Macrophage subpopulations in systemic lupus erythematosus. Discov Med (2012) 1.02
Molecular basis of 9G4 B cell autoreactivity in human systemic lupus erythematosus. J Immunol (2013) 1.00
Fas death receptor signaling represses monocyte numbers and macrophage activation in vivo. J Immunol (2004) 0.99
Urine proteome scans uncover total urinary protease, prostaglandin D synthase, serum amyloid P, and superoxide dismutase as potential markers of lupus nephritis. J Immunol (2010) 0.99
Adverse effects of simulated hyper- and hypo-phosphatemia on endothelial cell function and viability. PLoS One (2011) 0.99
Pro-apoptotic Bid is required for the resolution of the effector phase of inflammatory arthritis. Arthritis Res Ther (2007) 0.99
Proteomic toolbox for autoimmunity research. Autoimmun Rev (2009) 0.98
Lupus nephritis: current update. Arthritis Res Ther (2011) 0.97
The lupus-susceptibility locus, Sle3, mediates enhanced resistance to bacterial infections. J Immunol (2006) 0.97
Dysregulated expression of CXCR4/CXCL12 in subsets of patients with systemic lupus erythematosus. Arthritis Rheum (2010) 0.95
The lupus susceptibility locus Sle1 breaches peripheral B cell tolerance at the antibody-forming cell and germinal center checkpoints. J Immunol (2009) 0.95
Bim-Bcl-2 homology 3 mimetic therapy is effective at suppressing inflammatory arthritis through the activation of myeloid cell apoptosis. Arthritis Rheum (2010) 0.95
Kallikrein transduced mesenchymal stem cells protect against anti-GBM disease and lupus nephritis by ameliorating inflammation and oxidative stress. PLoS One (2013) 0.95
Targeting the CXCR4/CXCL12 axis in systemic lupus erythematosus. Expert Opin Ther Targets (2009) 0.94
Experimental anti-GBM nephritis as an analytical tool for studying spontaneous lupus nephritis. Arch Immunol Ther Exp (Warsz) (2008) 0.94
The lupus-prone NZM2410/NZW strain-derived Sle1b sublocus alters the germinal center checkpoint in female mice in a B cell-intrinsic manner. J Immunol (2012) 0.94
Enhanced egg-induced immunopathology correlates with high IFN-gamma in murine schistosomiasis: identification of two epistatic genetic intervals. J Immunol (2005) 0.93
Deficiency of type I interferon contributes to Sle2-associated component lupus phenotypes. Arthritis Rheum (2005) 0.93
PI3K/AKT signaling and systemic autoimmunity. Immunol Res (2005) 0.92
Modulating proximal cell signaling by targeting Btk ameliorates humoral autoimmunity and end-organ disease in murine lupus. Arthritis Res Ther (2012) 0.92
SLE 1, 2, 3...genetic dissection of lupus. Adv Exp Med Biol (2007) 0.92
Similar CD19 dysregulation in two autoantibody-associated autoimmune diseases suggests a shared mechanism of B-cell tolerance loss. J Clin Immunol (2006) 0.92
What do mouse models teach us about human SLE? Clin Immunol (2006) 0.92
Inflammation associated anemia and ferritin as disease markers in SLE. Arthritis Res Ther (2012) 0.90
Urinary angiostatin--a novel putative marker of renal pathology chronicity in lupus nephritis. Mol Cell Proteomics (2013) 0.90
The AKT axis as a therapeutic target in autoimmune diseases. Endocr Metab Immune Disord Drug Targets (2009) 0.90
Latent membrane protein 1, the EBV-encoded oncogenic mimic of CD40, accelerates autoimmunity in B6.Sle1 mice. J Immunol (2010) 0.89
Genetic dissection of systemic lupus erythematosus pathogenesis: evidence for functional expression of Sle3/5 by non-T cells. J Immunol (2002) 0.89
Superoxide dismutase mimetic drug tempol aggravates anti-GBM antibody-induced glomerulonephritis in mice. Am J Physiol Renal Physiol (2010) 0.88
PI3K/AKT/mTOR hypersignaling in autoimmune lymphoproliferative disease engendered by the epistatic interplay of Sle1b and FASlpr. Int Immunol (2007) 0.88
Anti-nuclear antibody reactivity in lupus may be partly hard-wired into the primary B-cell repertoire. Mol Immunol (2009) 0.87
Molecular signatures of antinuclear antibodies-contributions of heavy chain CDR residues. Mol Immunol (2002) 0.87
IgG and IgM autoantibody differences in discoid and systemic lupus patients. J Invest Dermatol (2012) 0.87
Strain distribution pattern of immune nephritis--a follow-up study. Int Immunol (2008) 0.85
CD19 hyperexpression augments Sle1-induced humoral autoimmunity but not clinical nephritis. Arthritis Rheum (2007) 0.85
Overexpression of membrane-bound fas ligand (CD95L) exacerbates autoimmune disease and renal pathology in pristane-induced lupus. J Immunol (2013) 0.85
Altered B-cell signaling in lupus. Autoimmun Rev (2008) 0.84
The lipopolysaccharide-triggered mesangial transcriptome: Evaluating the role of interferon regulatory factor-1. Kidney Int (2005) 0.84
Prevention of murine lupus nephritis by targeting multiple signaling axes and oxidative stress using a synthetic triterpenoid. Arthritis Rheumatol (2014) 0.83
Urinary vascular cell adhesion molecule, but not neutrophil gelatinase-associated lipocalin, is associated with lupus nephritis. J Rheumatol (2012) 0.83
Biological specificity of CDK4/6 inhibitors: dose response relationship, in vivo signaling, and composite response signature. Oncotarget (2017) 0.82
RANTES deficiency attenuates autoantibody-induced glomerulonephritis. J Clin Immunol (2010) 0.82
Glutathione S-transferase Mu 2-transduced mesenchymal stem cells ameliorated anti-glomerular basement membrane antibody-induced glomerulonephritis by inhibiting oxidation and inflammation. Stem Cell Res Ther (2014) 0.82
Molecular signatures of anti-nuclear antibodies: contributions of specific light chain residues and a novel New Zealand Black V kappa 1 germline gene. J Immunol (2003) 0.82
Systemic lupus erythematosus--recent clues from congenic strains. Arch Immunol Ther Exp (Warsz) (2005) 0.81
Proteomics in rheumatology: the dawn of a new era. F1000 Med Rep (2010) 0.81
Genetic basis of murine lupus nephritis. Semin Nephrol (2007) 0.81
Understanding B-cell tolerance through the use of immunoglobulin transgenic models. Immunol Res (2008) 0.81
Endothelial overexpression of Fas ligand decreases atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol (2004) 0.80
Enhanced expression of stem cell antigen-1 (Ly-6A/E) in lymphocytes from lupus prone mice correlates with disease severity. J Autoimmun (2005) 0.80
Serial non-invasive assessment of antibody induced nephritis in mice using positron emission tomography. PLoS One (2013) 0.80
Macrophages and neutrophils in SLE-An online molecular catalog. Autoimmun Rev (2011) 0.80
Identification of novel VH1/J558 immunoglobulin germline genes of C57BL/6 (Igh b) allotype. Mol Immunol (2005) 0.80
Natural trematode infection in liver of water buffalo (Bubalus bubalis): histopathological investigation. J Parasit Dis (2011) 0.80
Paraquat Poisoning Followed by Toxic Epidermal Necrolysis: A Report of Two Cases and Published Work Review. Dermatology (2015) 0.79
Serial non-invasive monitoring of renal disease following immune-mediated injury using near-infrared optical imaging. PLoS One (2012) 0.79
Molecular signatures of anti-nuclear antibodies--contribution of heavy chain framework residues. Mol Immunol (2003) 0.79
Inducible expression of kallikrein in renal tubular cells protects mice against spontaneous lupus nephritis. Arthritis Rheum (2013) 0.79
Genetic underpinnings of autoimmunity--lessons from studies in arthritis, diabetes, lupus and multiple sclerosis. Curr Opin Immunol (2003) 0.78
Molecular hallmarks of anti-chromatin antibodies associated with the lupus susceptibility locus, Sle1. Mol Immunol (2009) 0.78
Protein kinase Cβ is required for lupus development in Sle mice. Arthritis Rheum (2013) 0.78
The role of rearrangement at the second Ig heavy chain locus in maintaining B cell tolerance to DNA. J Immunol (2008) 0.77
Three pathogenic determinants in immune nephritis--anti-glomerular antibody specificity, innate triggers and host genetics. Front Biosci (2007) 0.77